Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
Group Sign-on Letter to Congress Opposing Proposed Amendments to Section 101 of the Patent Act
-
ACMG Comments to CMS Regarding NCD 90.2 and Medicare Coverage of NGS for Advanced Cancer
-
Group Sign-on Letter to CMS Requesting Extension of Comment Period Regarding NGS Coverage Reconsideration
-
Group Sign-on Letter to Congress Supporting the Medical Nutrition Equity Act (MNEA)
-
ACMG Letter to Congress Regarding the Advancing Access to Precision Medicine Act
-
Group Sign-on Letter to CMS Requesting Revision of Interpretation of NCD for NGS for Advanced Cancer
-
ACMG Letter to Congress Concerning Legislation for Reimbursement of Genetic Counseling Services
-
ACMG Letter to Congress Concerning Legislation for Reimbursement of Genetic Counseling Services
-
ACMG Comments to CMS Concerning CLFS Gapfill Preliminary Determinations for GS Codes 81425, 81426, and 81427
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations